Business

India’s Biggest Drugmaker Plans to Start Developing Its Own Medicines

Sun Pharma looks beyond generics.

Dilip Shanghvi, founder and largest shareholder of Sun Pharmaceutical Industries, in 2015.
Photographer: Danish Siddiqui/Reuters

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Ari Altstedter

May 22, 2019 at 8:00 AM UTC

This article is for subscribers only.

This article is part of the May 27, 2019 issue of businessweek.

Want more news about the future of health care? Sign up here for Bloomberg’s Prognosis newsletter to get great stories delivered to your inbox every Thursday.

You’d be hard-pressed to find someone who’s lost more during the recent upheaval in the generic drug business than Dilip Shanghvi: He forfeited $17 billion to be precise, plus the title of India’s richest man.